MK-2866 and Rosuvastatin Interaction

Avoid
Mechanism-based 64% confidence

MK-2866 and Rosuvastatin have a potentially harmful interaction with 64% confidence. Both MK-2866 and Rosuvastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the heart, so monitoring these systems is recommended.

Compound Profiles

MK-2866

Selective Androgen Receptor Modulator | Muscle Wasting Research

MK-2866 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a partial agonist in muscle and bone tissue. Upon binding, the MK-2866-AR complex undergoes a conformational change that promotes nuclear translocation and interaction with androgen response elements (AREs) on DNA, activating transcription of genes involved in protein synthesis, nitrogen retention, and myogenic differentiation.

Half-life: ~24 hours Typical dose: 10-25 mg/day oral sarm, anabolic
androgen receptormtormyostatin androgeniccarcinogenic riskhepatotoxichpta suppressive
View full profile

Rosuvastatin

HMG-CoA Reductase Inhibitor | Statin for Lipid Management

Rosuvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway responsible for hepatic cholesterol synthesis. By blocking this enzyme, rosuvastatin reduces intracellular cholesterol in hepatocytes, which triggers upregulation of LDL receptor expression on the liver cell surface.

Half-life: ~19 hours Typical dose: 5-20 mg/day cardiovascular
hepatotoxiclipid disruptingteratogenic
View full profile

Combined Organ Load

Gonads
moderate
Heart
moderate
Liver
moderate

Shared Safety Flags

2x 2 hepatotoxic compounds (MK-2866, Rosuvastatin). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 compounds disrupt lipids (MK-2866, Rosuvastatin). Get lipid panel mid-cycle — consider adding lipid support.

Frequently Asked Questions

Can I take MK-2866 with Rosuvastatin?

Combining MK-2866 with Rosuvastatin is not recommended. Both MK-2866 and Rosuvastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is MK-2866 and Rosuvastatin safe together?

This combination carries significant risk. Both MK-2866 and Rosuvastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between MK-2866 and Rosuvastatin?

Both MK-2866 and Rosuvastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time MK-2866 and Rosuvastatin?

MK-2866 has a half-life of ~24 hours and Rosuvastatin has a half-life of ~19 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: MK-2866 vs Rosuvastatin

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.